The worldwide medtech spectrum is undergoing a phenomenal shift, mostly driven due to the meteoric rise when it comes to Chinese companies. The narrative was absolutely simple for decades-China made things cheap. However, that tale is now dangerously outdated. The fact is that today Chinese medtech companies aren’t just competing; they are increasingly setting the pace when it comes to innovation, international reach, and quality.
The role of China in international medtech trade has grown prominently. In 2000, China accounted for less than 3% of the international trade when it came to medtech products. However, by 2021, the share of China had risen to 12.4% of the total international exports, thereby amounting to almost $40 billion.
The medical device market in China has grown quite significantly, thereby reinforcing its position as a worldwide manufacturing leader. By the end of 2023, China went on to have over 32,000 medical device manufacturers, which generated more than $160 billion. This progress is primarily driven due to government initiatives, rising innovation within the healthcare sector of the country as well as robust domestic demand.
National strategies such as Made in China 2025, go on to prioritise medtech, thereby setting phenomenal goals for domestic production when it comes to mid- to high-end devices – 70% by 2025 and 95% by 2030.
Driven due to government incentives like 100% super tax as well as the market competition, the Chinese medtech companies are investing phenomenally in research and development. It is well to be noted that leading companies now go on to dedicate 11 to 14% of their revenue to research and development, thereby passing the 6 to 8% average, which is mostly seen among their western peers.
Moreover, to complement domestic growth and also rapidly acquire worldwide reach, the Chinese medtech companies are actively making use of strategic partnerships as well as acquisitions. Chinese medtech companies are also making utmost use of a powerful mix of labor that’s affordable, growing technical depth in order to manufacture high-quality devices at lower cost, and proximity to supplies.
Apart from this, when it comes to investors, significant opportunities exist, especially when it comes to high-growth areas in which Chinese firms show their leadership, like digital health as well as artificial intelligence. Engaging in a proactive way with this evolving ecosystem is indeed the key to thriving in the global healthcare innovation future.
